<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03363984</url>
  </required_header>
  <id_info>
    <org_study_id>ID-082-102</org_study_id>
    <nct_id>NCT03363984</nct_id>
  </id_info>
  <brief_title>Pharmacokinetic Interaction Between Midazolam and ID-082 in Healthy Subjects</brief_title>
  <official_title>A Single-center, Open-label Study to Investigate the Effect of a Single Oral Dose and Repeated Oral Doses of ID-082 on the Pharmacokinetics of Midazolam and Its Metabolite 1-hydroxymidazolam in Healthy Male Subjects.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Idorsia Pharmaceuticals Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Idorsia Pharmaceuticals Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A clinical study in healthy male subjects to investigate whether the administration of ID-082
      can affect the fate in the body (amount and time of presence in the blood) of midazolam.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 27, 2017</start_date>
  <completion_date type="Actual">December 19, 2017</completion_date>
  <primary_completion_date type="Actual">December 19, 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cmax of midazolam</measure>
    <time_frame>From baseline to EOS (i.e. for up to 16 days)</time_frame>
    <description>Maximum plasma concentration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC0-24 of midazolam</measure>
    <time_frame>From baseline to EOS (i.e. for up to 16 days)</time_frame>
    <description>Area under the plasma concentration-time curvefrom time zero to 24 h</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cmax of 1-hydroxymidazolam</measure>
    <time_frame>From baseline to EOS (i.e. for up to 16 days)</time_frame>
    <description>Maximum plasma concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC0-inf of midazolam and 1-hydroxymidazolam and AUC0-24 of 1-hydroxymidazolam</measure>
    <time_frame>From baseline to EOS (i.e. for up to 16 days)</time_frame>
    <description>Area under the plasma concentration-time curve from zero to infinity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>tmax of midazolam and 1-hydroxymidazolam</measure>
    <time_frame>From baseline to EOS (i.e. for up to 16 days)</time_frame>
    <description>Time to reach maximum plasma concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>tÂ½ of midazolam and 1-hydroxymidazolam</measure>
    <time_frame>From baseline to EOS (i.e. for up to 16 days)</time_frame>
    <description>Terminal elimination half-life</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total body apparent plasma clearance (CL/F) of midazolam</measure>
    <time_frame>From baseline to EOS (i.e. for up to 16 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Metabolic ratio (MR) of the AUC0-24 of 1-hydroxymidazolam to the AUC0-24 of midazolam</measure>
    <time_frame>From baseline to EOS (i.e. for up to 16 days)</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Midazolam &amp; ID-082</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single oral administration of 2 mg midazolam on Day 1, Day 2, and Day 11. Administration of ID-082 from Day 2 through Day 11.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Midazolam</intervention_name>
    <description>Single oral administration of 2 mg midazolam under fasted conditions/outside of meal times</description>
    <arm_group_label>Midazolam &amp; ID-082</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ID-082</intervention_name>
    <description>Administration of ID-082 under fasted conditions/outside of meal times</description>
    <arm_group_label>Midazolam &amp; ID-082</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Signed informed consent in the local language prior to any study-mandated procedure;

          -  Healthy male subjects aged 18 to 45 years (inclusive) at screening;

          -  Male subject with a female partner of childbearing potential or a pregnant partner
             must agree to use a condom from screening, during the study, and for at least 3 months
             after last study treatment intake;

          -  Body mass index of 18.0 to 30.0 kg/m2 (inclusive) at screening;

          -  Healthy on the basis of physical examination, cardiovascular assessments and
             laboratory tests.

        Exclusion Criteria:

          -  Contraindication or known hypersensitivity to ID-082, midazolam or drugs of the same
             classes, or any of their excipients;

          -  Modified Swiss Narcolepsy Scale total score &lt; 0 at Screening or history of narcolepsy
             or cataplexy;

          -  History or clinical evidence of any disease and/or existence of any surgical or
             medical condition which might interfere with the absorption, distribution, metabolism
             or excretion of the study treatment;

          -  Known hypersensitivity or allergy to natural rubber latex;

          -  Known hereditary problems of fructose intolerance, glucose-galactose malabsorption, or
             sucrose-isomaltase insufficiency;

          -  Previous history of fainting, collapse, syncope, orthostatic hypotension, or vasovagal
             reactions;

          -  Any circumstances or conditions, which, in the opinion of the investigator, may affect
             full participation in the study or compliance with the protocol.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Fabienne Le Gac</last_name>
    <role>Study Director</role>
    <affiliation>Idorsia Pharmaceuticals Ltd.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Simbec Research Limited</name>
      <address>
        <city>Merthyr Tydfil</city>
        <state>Mid Galmorgan</state>
        <zip>CF48 4DR</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 21, 2017</study_first_submitted>
  <study_first_submitted_qc>November 30, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">December 6, 2017</study_first_posted>
  <last_update_submitted>January 11, 2018</last_update_submitted>
  <last_update_submitted_qc>January 11, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 12, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Midazolam</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

